Company intelligence / Profile preview

Noscira S.A.

Tres Cantos/Madrid, Community of Madrid, Spainorpha.net ↗

Ownership: Private
Development stage: Phase 2

Overview

Noscira developed small molecule drugs targeting neurodegenerative diseases, notably Alzheimer’s disease and progressive supranuclear palsy. Its lead compound, Tideglusib (NP‑12/Nypta/Zentylor), showed positive results in Phase IIa trials for Alzheimer’s but was discontinued after further development. The company also received orphan drug status and fast track designation from the FDA and EU for Tideglusib in progressive supranuclear palsy. As of the latest available data, all programs have been discontinued and the company is no longer active.

Therapeutic areas: Neurology
Modalities: Small molecules (notably GSK-3β inhibitors, AChE inhibitors)
Industry: Biotech

Drug pipeline

1 asset

NP031

Discontinued

Partnerships

Pharmamar/Grupo Zeltia – parent group collaboration on marine-derived drug discovery

Beyond the preview

Go deeper on Noscira S.A..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Noscira S.A..

Explore the full profile